Pune, Nov. 17, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Custom Antibody Market will clock US$ 96.78 billion by 2030. The rapidly increasing adoption of digitalization due to growing urbanization is a major driver for the Custom Antibody Market. This exclusive information is published by Growth Plus Reports in its report titled “Custom Antibody Market – Global Outlook & Forecast 2022-2030
Download Sample PDF Brochure of Custom Antibody Market:
https://growthplusreports.com/inquiry/request-sample/custom-antibody-market/7965
Market Drivers
The main growth drivers for this market are an increase in research activity, particularly in the life sciences sector, and expanding industry-academia partnerships. Additionally, obtaining an antibody that performs well in a certain qualitative or quantitative immunodetection approach is the goal of producing tailored antibodies. End users choose custom-made antibodies primarily because the quality of catalogue antibodies (to assure the reproducibility of results) is an area of concern in this market. Additionally, hospitals mostly utilise custom antibodies to identify cancer, immune system disorders, and other illnesses. An increase of hospitals, increased government spending on healthcare, and greater disease awareness are the main market-driving factors. Over the projected period, the need for custom antibody services will also increase as personalised cancer care becomes more prevalent. Furthermore, in recent years, there has been a noticeable rise in the demand for the latest diagnostic medical methods. This expansion can be attributed to rising prevalence rates, a general audience that has approved tailored items with high-quality standards, rising healthcare spending, and increased awareness for public health issues among technology advancements.
Excerpts from ‘By Type Segmentation’
Based on type, the global custom antibody market has been segmented into
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibody.
The monoclonal antibody segment dominated the market during forecast period. This is due to the fact that monoclonal antibodies are the best option for all types of research studies due to their high specificity and selectivity compared to other antibodies. Standard methods including ELISA, western blotting, flow cytometry, and other similarity-based tests or isolation procedures typically use monoclonal antibodies. A monoclonal antibody aids in the recognition of a specific target antigen in ELISA. Additionally, monoclonal antibodies can aid in the separation of certain cells in flow cytometry. In the process of purifying proteins, monoclonal antibodies are also useful. An isolated protein from the solution can be created using the monoclonal antibody.
Excerpts from ‘By Region Segmentation’
Based on region, the global custom antibody market has been segmented into
- North America
- Europe
- Asia Pacific
- Rest Of The World
The market is developing in the North American region due to a number of causes, including increasing research activity and funding, quality issues with catalogue antibodies, an expanding pipeline of antibody therapies, and industry-academia partnerships. During the anticipated period, the Asia Pacific region's market has grown the fastest. Japan dominates the Asia Pacific market for customised antibodies. This is explained by the existence of significant market participants and their participation in product development. In addition, there is a high demand for research, increased government backing, changing illness profiles, and rising funding activities, all of which are fostering the development of biotechnology.
Excerpts from ‘Competitive Landscape’
Some of the prominent market players in the global custom antibody market include
- Thermo Fisher Scientific Inc.
- Merck Kgaa
- Cell Signaling Technology Inc.
- Sino Biological, Inc.
- Rockland Immunochemicals
- Biolegend
- Creative Diagnostics
- Genscript
- Bio-Rad Laboratories Inc.
- Abcam Plc
- Agilent Technologies
- Innovagen Ab
- Promab Biotechnologies
- Proteogenix
- Boster Biological Technology
Market participants are concentrating on the development of technically advanced antibodies for a variety of research and therapeutic applications. For instance, the science and technology business Merck Group recently revealed that ZooMAb, a new class of monoclonal antibodies that are precisely tailored, reduces the usage of animals in research. The approach makes it possible to produce antibodies from a variety of species without having to undergo laborious cell fusion or hybridoma production. Once the antibody's gene sequence has been discovered, it may be generated without endangering or killing any animals, providing an almost endless supply of the monoclonal antibody with outstanding batch-to-batch consistency.
Inquire Before Buying This Research Report:
https://growthplusreports.com/inquiry/before-buying/custom-antibody-market/7965
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years - 2020
- Base Years - 2021
- Forecasted Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trend (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL CUSTOM ANTIBODY MARKET - ANALYSIS & FORECAST, BY TYPE
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibody
- GLOBAL CUSTOM ANTIBODY MARKET - ANALYSIS & FORECAST, BY SERVICES
- Antibody Development
- Antibody Production & Purification
- Antibody Fragmentation & Labelling
- GLOBAL CUSTOM ANTIBODY MARKET - ANALYSIS & FORECAST, BY SOURCE
- Rabbit and Mice
- GLOBAL CUSTOM ANTIBODY MARKET - ANALYSIS & FORECAST, BY END USER
- Pharmaceuticals & Biotechnology Companies
- Hospital & Clinics
- Academic and Research Institute
- Contact Research Organization
Scope of the Report:
| Report Attribute | Details |
| Market size value in 2021 | US$ 41.72 billion |
| Revenue forecast in 2030 | US$ 96.78 billion |
| Growth Rate | CAGR of 10% from 2022 to 2030 |
| Base year for estimation | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | type, service, source, end user and region. |
| Regional scope | North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pipeline Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Quickly Purchase Premium Copy of Custom Antibody Market Report:
About Us
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
